PT  - JOURNAL ARTICLE
AU  - Aggarwal, Geetika
AU  - Malmstrom, Theodore K.
AU  - Miller, Douglas K.
AU  - Morley, John E.
AU  - Nguyen, Andrew D.
AU  - Butler, Andrew A.
TI  - Low serum adropin levels predict poor cognitive performance in late middle-aged African Americans
AID  - 10.1101/2021.12.09.21267550
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2021.12.09.21267550
4099  - http://medrxiv.org/content/early/2023/01/11/2021.12.09.21267550.short
4100  - http://medrxiv.org/content/early/2023/01/11/2021.12.09.21267550.full
AB  - Adropin, a secreted peptide that is predominantly expressed in the brain, regulates processes that are important for maintaining cognitive functions. Whether circulating levels correlate with cognitive ability, and the factors regulating brain expression, are not known. Here we report circulating adropin levels correlate with risk of poor cognitive performance (scoring in the lowest quintile for a composite cognitive score) in the African American Health Study (n=352, mean age 56.6yr, STD 4.4yr, range 45 to 65yr). Risk of poor cognitive performance declined with increasing adropin levels (OR=0.715, p<0.01). This relationship is more pronounced in people with impaired glycemic control (OR=0.532, P<0.05). Adropin is highly expressed in cultured human astrocytes, where its expression correlates inversely with age, positively with transcriptomic signatures of energy metabolism and macromolecule synthesis and is suppressed by pro-inflammatory factors. Together, suppression of adropin expression in astrocytes is a plausible link between aging, inflammation, and risk of cognitive impairment.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAAB was supported by the NINDS, NIH (R21NS108138). AAB and ADN acknowledge financial support provided by Saint Louis University. African American Health was supported by a grant from the National Institute on Aging (R01 AG010436 to DKM).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All study procedures were approved by the Institutional Review Board at Saint Louis University and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors